Lyrica's DEA Scheduling Will Not Hold Back Sales, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer CEO McKinnell says "the level of scheduling we're anticipating...should not have a significant impact on our opportunity" with Lyrica. Pfizer will work to lift DEA's scheduling for Lyrica, Senior VP Feczko says.